US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 13.5100
- -0.8500-5.92%
Close May 6 16:00 ET
- 13.0000
- -0.5100-3.77%
Post 19:08 ET
13.97MMarket Cap-118P/E (TTM)
14.9900High13.2700Low34.74KVolume14.3600Open14.3600Pre Close480.46KTurnover4.04%Turnover RatioLossP/E (Static)1.03MShares1130.400052wk High1.91P/B11.63MFloat Cap3.950152wk Low--Dividend TTM860.98KShs Float22031.7120Historical High--Div YieldTTM11.98%Amplitude3.9501Historical Low13.8310Avg Price1Lot Size
Avalo Therapeutics News
Avalo Therapeutics Analyst Ratings
Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
RBC Capital Downgrades Avalo Therapeutics to Sector Perform, Lowers Price Target to $0.75
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
RBC Capital Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $9
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier
Avalo Therapeutics Analyst Ratings
Jefferies Downgrades Avalo Therapeutics to Underperform, Announces $3 Price Target
Avalo Therapeutics (AVTX) Gets a Buy From RBC Capital
No More
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg